SCHEMBL5401423

SCHEMBL5401423

CC(C)c1nnc(NS(=O)(=O)c2ccc(Oc3ccccc3)cc2)s1

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.75
HSD17B10 Q99714 3/20 0.75
HPGD P15428 3/20 0.51
PKM P14618 2/20 0.51
PGR P06401 2/20 0.50
FFAR1 O14842 1/20 0.50
CA1 P00915 1/20 0.49
GGT1 P19440 1/20 0.49
KDM4E B2RXH2 3/20 0.49
LMNA P02545 3/20 0.49
ATM Q13315 1/20 0.49
MAPT P10636 1/20 0.48
TSHR P16473 1/20 0.48
AKT1 P31749 1/20 0.47
TARS1 P26639 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5395237 0.86 ALDH1A1 (0.68) ALDH1A1HSD17B10PKMCA1LMNA
SCHEMBL5406688 0.82 ALDH1A1 (0.67) ALDH1A1HSD17B10HPGDPKMLMNA
SCHEMBL1451365 0.81 ALDH1A1 (0.73) ALDH1A1HSD17B10HPGDPKMCA1
SCHEMBL5398574 0.81 ALDH1A1 (0.73) ALDH1A1HSD17B10HPGDPKMCA1
SCHEMBL1451656 0.81 ALDH1A1 (0.51) ALDH1A1HSD17B10FFAR1LMNAMAPT
SCHEMBL5401437 0.81 LMNA (0.71) ALDH1A1HSD17B10HPGDPKMPGR
SCHEMBL5388827 0.80 ALDH1A1 (0.71) ALDH1A1HSD17B10HPGDPKMCA1
SCHEMBL5401314 0.80 ALDH1A1 (0.71) ALDH1A1HSD17B10HPGDPKMCA1
Glyprothiazol SCHEMBL1814714 0.80 ALDH1A1 (0.71) ALDH1A1HSD17B10HPGDPKMCA1
SCHEMBL5404610 0.80 ALDH1A1 (0.71) ALDH1A1HSD17B10CA1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 53/4885HSD17B10 22/4885HPGD 44/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 ALDH1A1 36/4885HSD17B10 16/4885HPGD 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.